Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMO Cleared To Market Myopia IOL; Staar Surgical Awaits Site Re-Inspection

This article was originally published in The Gray Sheet

Executive Summary

Ophtec/Advanced Medical Optics will start U.S. clinical trials next spring for a foldable version of their phakic intraocular lens to correct near-sightedness, building on two years of European study data

You may also be interested in...



AMO To Surround Eye Surgeons With Refractive Offerings After Visx Purchase

Advanced Medical Optics' acquisition of pure-play LASIK manufacturer Visx will enable the combined entity to more effectively market laser eye surgery to physicians performing both refractive and cataract procedures

AMO To Surround Eye Surgeons With Refractive Offerings After Visx Purchase

Advanced Medical Optics' acquisition of pure-play LASIK manufacturer Visx will enable the combined entity to more effectively market laser eye surgery to physicians performing both refractive and cataract procedures

Staar Surgical Visian ICL

Implantable contact lens PMA approval for myopia likely will be delayed beyond the Oct. 22 American Academy of Ophthalmologists meeting, the firm says, following Sept. 23 receipt of 36 "FDA 483" observations stemming from a re-inspection of its Monrovia, Calif. manufacturing facility. An initial inspection led to a December 2003 warning letter and subsequent Staar corrections. Current observations include quality system and complaint handling issues. Staar is preparing a written response and will undertake further corrective action (1"The Gray Sheet" Sept. 20, 2004, p. 3)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020890

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel